Oral HPV infection clearance and acquisition after nonavalent vaccination in men who have sex with men and transgender women: a prospective analysis

被引:1
作者
Rossotti, Roberto [1 ,2 ]
Nava, Alice [3 ]
Baiguera, Chiara [1 ]
Baldassari, Luca [1 ,4 ]
Moioli, Maria Cristina [1 ]
Fanti, Diana [3 ]
D'Amico, Federico [1 ]
Calzavara, Daniele [2 ]
Bossolasco, Simona [2 ,5 ]
Tamburini, Andrea Marco [6 ]
Canetti, Diana [2 ,5 ]
Bana, Nicholas Brian [1 ,4 ]
Cernuschi, Massimo [2 ,5 ]
Vismara, Chiara [3 ]
Puoti, Massimo [1 ,4 ]
机构
[1] ASST Grande Osped Metropolitano Niguarda, Dept Infect Dis, Piazza Osped Maggiore 3, I-20162 Milan, Italy
[2] Milano Checkpoint ETS, Milan, Italy
[3] ASST Grande Osped Metropolitano Niguarda, Clin Microbiol, Milan, Italy
[4] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy
[5] Ist Sci San Raffaele, Dept Infect Dis, Milan, Italy
[6] Ist Sci Univ San Raffaele, Gastrointestinal Surg Unit, Milan, Italy
关键词
Oral HPV infection; Nonavalent vaccine; MSM; HIV; Pre-exposure prophylaxis; HUMAN-PAPILLOMAVIRUS VACCINATION; YOUNG-ADULTS; IMMUNOGENICITY; SAFETY; PREVALENCE; NEOPLASIA;
D O I
10.1007/s10096-024-04887-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Oral HPV infection is the main risk factor for the development of oropharyngeal carcinoma. Men who have sex with men (MSM), especially if living with HIV (PLWH), are at increased risk of infection and consequently of cancer development. Aim of this study is to evaluate the impact of nonavalent vaccine on oral HPV infection in a cohort of MSM and transgender women (TGW). This prospective study included all MSM and TGW who started nonavalent HPV vaccination from May 2019 to September 2021. Oral rinse was collected before each vaccine administration and after six months of follow up. Descriptive statistics were used. Kaplan Meier probability curves and Cox regression models for HPV acquisition and clearance were calculated. The analysis included 211 individuals (202 MSM and 9 TGW). PLWH were 138 (65.4%). Baseline oral rinse was positive in 30 subjects (14.2%). Positivity rate did not change over time (p = 0.742), even when restricting the analysis only to high-risk genotypes (p = 0.575) and to genotypes covered by vaccine (p = 0.894). The risk to acquire HPV infection was 12.8% at one year and 33.4% at two years after vaccination. The probability to clear the infection was 67.6% at one year and 87.9% at two years. HIV infection had no impact on vaccine efficacy. Age above 45 years was the only factor associated to HPV acquisition (aHR 4.06, 95% CI 1.03-15.98, p = 0.045). Prevalence of oral HPV infection was higher in PLWH, but HIV had no impact on viral clearance or acquisition after vaccination.
引用
收藏
页码:1847 / 1854
页数:8
相关论文
共 38 条
  • [1] Cervical cancer and HPV infection: ongoing therapeutic research to counteract the action of E6 and E7 oncoproteins
    Almeida, Ana M.
    Queiroz, Joao A.
    Sousa, Fani
    Sousa, Angela
    [J]. DRUG DISCOVERY TODAY, 2019, 24 (10) : 2044 - 2057
  • [2] Prevalence of Oral Human Papillomavirus Infection: Impact of Sex, Race/Ethnicity, and Vaccination Status
    Berenson, Abbey B.
    Hirth, Jacqueline M.
    Chang, Mihyun
    [J]. CLINICAL INFECTIOUS DISEASES, 2022, 74 (07) : 1230 - 1236
  • [3] Immunogenicity and safety of the 9-valent HPV vaccine in men
    Castellsague, X.
    Giuliano, A. R.
    Goldstone, S.
    Guevara, A.
    Mogensen, O.
    Palefsky, J. M.
    Group, T.
    Shields, C.
    Liu, K.
    Maansson, R.
    Luxembourg, A.
    Kaplan, S. S.
    [J]. VACCINE, 2015, 33 (48) : 6892 - 6901
  • [4] Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States
    Chaturvedi, Anil K.
    Graubard, Barry I.
    Broutian, Tatevik
    Pickard, Robert K. L.
    Tong, Zhen-Yue
    Xiao, Weihong
    Kahle, Lisa
    Gillison, Maura L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) : 262 - +
  • [5] Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
    Chaturvedi, Anil K.
    Engels, Eric A.
    Pfeiffer, Ruth M.
    Hernandez, Brenda Y.
    Xiao, Weihong
    Kim, Esther
    Jiang, Bo
    Goodman, Marc T.
    Sibug-Saber, Maria
    Cozen, Wendy
    Liu, Lihua
    Lynch, Charles F.
    Wentzensen, Nicolas
    Jordan, Richard C.
    Altekruse, Sean
    Anderson, William F.
    Rosenberg, Philip S.
    Gillison, Maura L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4294 - 4301
  • [6] Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases
    Cheng, Max A.
    Farmer, Emily
    Huang, Claire
    Lin, John
    Hung, Chien-Fu
    Wu, T. -C.
    [J]. HUMAN GENE THERAPY, 2018, 29 (09) : 971 - 996
  • [7] Oropharyngeal HPV infection: prevalence and sampling methods among HIV-infected men in South Africa
    Chikandiwa, Admire
    Pisa, Pedro T.
    Chersich, Matthew F.
    Muller, Etienne E.
    Mayaud, Philippe
    Delany-Moretlwe, Sinead
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2018, 29 (08) : 776 - 780
  • [8] Choi H, 2019, INT BRAZ J UROL, V45, P361, DOI [10.1590/s1677-5538.ibju.2018.0355, 10.1590/S1677-5538.IBJU.2018.0355]
  • [9] A systematic review and meta-analysis of cytology and HPV-related biomarkers for anal cancer screening among different risk groups
    Clarke, Megan A.
    Deshmukh, Ashish A.
    Suk, Ryan
    Roberts, Jennifer
    Gilson, Richard
    Jay, Naomi
    Stier, Elizabeth A.
    Wentzensen, Nicolas
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (11) : 1889 - 1901
  • [10] Moving forward with human papillomavirus immunotherapies
    Cuburu, Nicolas
    Schiller, John T.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (11) : 2875 - 2880